Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Site Image

Study Overview

This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.

  • Study Identifier: 849568

Recruitment Status

Enrolling By Invitation

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu